HLA-A*33:01 在特比萘芬所致胆汁淤积性肝炎患者中的作用
研究连续纳入药物性肝损伤网络中的特比萘芬肝毒性高因果性病例,进行高分辨率 HLA 测序。15 例患者中位潜伏期 38 天,80% 出现黄疸,10/11 例欧洲裔携带 HLA-A*33:01、B*14:02、C*08:02 单体型,该单体型在欧洲裔人群对照中携带频率为 1.6%。
要点
- 特比萘芬肝毒性多表现为混合型或胆汁淤积型肝损伤,部分患者遗留慢性胆汁淤积性损伤证据。
- 欧洲裔患者中 HLA-A*33:01、B*14:02、C*08:02 单体型与特比萘芬肝损伤呈强遗传关联。
- 分子对接研究提示特比萘芬可能与 HLA-A*33:01 及 A*33:03 相互作用。
核心结论
- 特比萘芬肝毒性患者最常见表现为混合型或胆汁淤积型肝损伤,且常遗留慢性胆汁淤积性损伤证据。
- 在欧洲裔人群中确认了 HLA-A*33:01 与特比萘芬药物性肝损伤的强遗传关联。
研究设计与样本
- 研究回顾了连续纳入药物性肝损伤网络的特比萘芬肝毒性高因果性病例。
- DNA 样本使用 Ilumina MiSeq 平台进行高分辨率验证性 HLA 测序。
主要发现
- 全部 15 例特比萘芬肝毒性患者均超过 40 岁(中位数 57 岁),53% 为女性,中位潜伏期为 38 天(范围 24 至 114 天)。
- 药物性肝损伤起病时 80% 出现黄疸,血清丙氨酸氨基转移酶中位数为 448 U/L,碱性磷酸酶为 333 U/L。
- 随访期间 1 例因急性肝衰竭需肝移植,其余 13 例中 7 例(54%)在 6 个月时仍有持续肝损伤,其中 4 例在 24 个月时生化指标持续异常。
- 高分辨率 HLA 基因分型证实 11 例欧洲裔参与者中 10 例(91%)携带 HLA-A*33:01、B*14:02、C*08:02 单体型,该单体型在欧洲裔人群对照中携带频率为 1.6%。
- 1 例非洲裔美国患者也为 HLA-A*33:01 携带者,2 例东亚患者携带相似 HLA 型别 A*33:03。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Terbinafine is an antifungal agent that has been associated with rare instances of hepatotoxicity. In this study we aimed to describe the presenting features and outcomes of patients with terbinafine hepatotoxicity and to investigate the role of human leukocyte antigen (HLA)-A*33:01. METHODS: Consecutive high causality cases of terbinafine hepatotoxicity enrolled into the Drug Induced Liver Injury Network were reviewed. DNA samples underwent high-resolution confirmatory HLA sequencing using the Ilumina MiSeq platform. RESULTS: All 15 patients with terbinafine hepatotoxicity were more than 40 years old (median = 57 years), 53% were female and the median latency to onset was 38 days (range 24 to 114 days). At the onset of drug-induced liver injury, 80% were jaundiced, median serum alanine aminotransferase was 448 U/L and alkaline phosphatase was 333 U/L. One individual required liver transplantation for acute liver failure during follow-up, and 7 of the 13 (54%) remaining individuals had ongoing liver injury at 6 months, with 4 demonstrating persistently abnormal liver biochemistries at month 24. High-resolution HLA genotyping confirmed that 10 of the 11 (91%) European ancestry participants were carriers of the HLA-A*33:01, B*14:02, C*08:02 haplotype, which has a carrier frequency of 1.6% in European Ancestry population controls. One African American patient was also an HLA-A*33:01 carrier while 2 East Asian patients were carriers of a similar HLA type: A*33:03. Molecular docking studies indicated that terbinafine may interact with HLA-A*33:01 and A*33:03. CONCLUSIONS: Patients with terbinafine hepatotoxicity most commonly present with a mixed or cholestatic liver injury profile and frequently have residual evidence of chronic cholestatic injury. A strong genetic association of HLA-A*33:01 with terbinafine drug-induced liver injury was confirmed amongst Caucasians. LAY SUMMARY: A locus in the human leukocyte antigen gene (HLA-A*33:01, B*14:02, C*08:02) was significantly overrepresented in Caucasian and African American patients with liver injury attributed to the antifungal medication, terbinafine. These data along with the molecular docking studies demonstrate that this genetic polymorphism is a plausible risk factor for developing terbinafine hepatotoxicity and could be used in the future to help doctors make a diagnosis more rapidly and confidently.
引用
- Fontana RJ, Cirulli ET, Gu J, et al. The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine. J Hepatol. 2018. PMID: 30138689. doi:10.1016/j.jhep.2018.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。